Latest Centocor Stories
MONROVIA, Calif., Jan. 17, 2013 /PRNewswire/ -- Xencor, Inc. today announced it has received a milestone payment from Janssen Research & Development, LLC (Janssen R&D) resulting from the exercised option for the use of Xencor's Xtend(TM) half-life extension technology in a therapeutic antibody. This triggered a payment to Xencor under the terms of a technology license agreement that the company entered into with Janssen R&D (f/k/a Centocor Research & Development,...
SAN DIEGO, Jan. 4, 2013 /PRNewswire/ -- Receptos, Inc., announced today that its selective sphingosine?1? phosphate 1 receptor (S1P1R) modulator, RPC1063, has been administered to the first patient in a Phase 2 study examining the clinical efficacy and safety of induction therapy in patients with moderately to severely active ulcerative colitis (UC). Leading to the initiation of the RPC01-202 study, called TOUCHSTONE, Receptos successfully filed an Investigational New Drug (IND)...
NEW BRUNSWICK, N.J., Jan. 2, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2013 of $0.61 per share on the company's common stock. The dividend is payable on March 12, 2013, to shareholders of record at the close of business on Feb. 26, 2013. The ex-dividend date is Feb. 22, 2013. About Johnson & JohnsonCaring for the world, one person at a time...inspires and unites the...
Parker Waichman LLP has filed a lawsuit on behalf of a woman who was implanted with the Prolift and Gynemesh, two transvaginal mesh implants manufactured by Johnson & Johnson/Ethicon. The case alleges that the devices are defective and caused substantial injury. New York, NY (PRWEB) December 14, 2012 Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective medical devices, has filed a lawsuit alleging that transvaginal mesh devices...
NEW BRUNSWICK, N.J., Nov. 30, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has elected Alex Gorsky Chairman, Board of Directors of Johnson & Johnson. Mr. Gorsky will assume the Chairman title and additional leadership responsibilities for the global health care company on Dec. 28, 2012; Mr. Gorsky was appointed Chief Executive Officer of Johnson & Johnson in April 2012. Current Chairman Bill Weldon will step down as...
WASHINGTON, Nov. 12, 2012 /PRNewswire/ -- New Phase 3 findings from a Janssen Research & Development, LLC (Janssen)-sponsored study showed treatment with the investigational intravenous (I.V.) therapy golimumab, a tumor necrosis factor (TNF) inhibitor, significantly inhibited radiographic progression in patients with active moderate to severe rheumatoid arthritis (RA) despite treatment with methotrexate. Analysis of study patients' X-rays showed significant inhibition of the...
NEW BRUNSWICK, N.J., Nov. 7, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Credit Suisse 2012 Healthcare Conference Wednesday, Nov. 14(th), at the Arizona Biltmore Hotel, 2400 E. Missouri Avenue, Phoenix, AZ. Dominic Caruso, Vice President, Finance & Chief Financial Officer, will represent the company in a session scheduled at 11:00 a.m. (Mountain Standard Time). This broadcast will be available to interested investors and parties by accessing...
NEW BRUNSWICK, N.J., Nov. 2, 2012 /PRNewswire/ -- Janssen and Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast for investors and other interested parties on Saturday, November 10, at approximately 5:00 p.m., Eastern Time, to coincide with the American College of Rheumatology (ACR) Annual Meeting being held in Washington, D.C. The presentation will highlight new, pivotal Phase 3 study findings, including; Intravenous Golimumab Inhibits Radiographic Progression...
NEW BRUNSWICK, N.J., Oct. 30, 2012 /PRNewswire/ -- Given the state of emergency in New Jersey due to Hurricane Sandy, Johnson & Johnson (NYSE: JNJ) announced that it will postpone the company's Medical Devices & Diagnostics business review for the investment community, which was scheduled for Thursday, Nov. 1(st). The company made the postponement decision to ensure the safety of its employees and expected attendees in the aftermath of the storm. A new date for the...
NEW BRUNSWICK, N.J., Oct. 25, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a Medical Devices & Diagnostics business review for the investment community beginning at 8:30 a.m. (Eastern Time) on Thursday, November 1(st )at the Hyatt Regency Hotel in New Brunswick, N.J. The program will include presentations by Johnson & Johnson's senior management representing our Medical Devices & Diagnostics segments. Dominic Caruso, Vice President, Finance and Chief...
